Dr. Inder Kaul Joins Asiatic Clinical Research as Independent Director

ALPHARETTA, Ga.--(BUSINESS WIRE)-- Dr. Inder Kaul, MD, MPH, has joined Asiatic Clinical Research (www.asiaticlinical.com; 'Asiatic') as an Independent Director.

Dr. Kaul brings his experience in clinical development – on both sides of the table – in drug development and CRO services. Dr. Kaul has two decades of progressive experience with small to large size companies in the product development programs of drugs, biologics and devices. He has extensive clinical experience in patient management including acute care, evaluation and testing, and knowledge of epidemiology and biostatistics.

Dr. Kaul is currently the Chief Medical Officer at Waltham, MA-based Artisan Pharma. Bindhu Aravapalli, Managing Director of Asiatic, said that with Dr. Kaul’s guidance, Asiatic will deliver what it promises in terms of service, quality and compliance in conducting clinical trials.

“Dr. Kaul is known globally for his expertise in directing scores of clinical trials (Phase I-IV) across many therapeutic areas such as infectious diseases, immunology, cardiovascular, rheumatology, and metabolic diseases,” said Aravapalli.

Prior to joining Artisan Pharma, Dr. Kaul served as Vice President of Clinical Development, Medical and Regulatory Affairs at Oscient Pharma. His responsibilities included leading new drug product development efforts and providing strategic and tactical leadership in all facets of drug development for two commercial products (ANTARA® and FACTIVE®), and an investigational agent Ramoplanin (a novel glycolipodepsipeptide antibiotic).

Dr. Kaul has also held senior-level management positions at a number of well-known companies. Some of them are:

  • Eight years at Abt Associates Clinical Trials. As Division Vice President – his last position there – Dr. Kaul spearheaded operations and supervised clinical contracts, including medical monitoring;
  • Medical and Technical Research Associates: Vice-President of Clinical and Medical Affairs;
  • Searle (now Pfizer): Served as Director of International Operations, responsible for all medical aspects related to approval of drugs;
  • Boehringer Ingelheim Pharmaceuticals, Inc.: Associate Director of Clinical Research;
  • Parexel International Corporation: Director of Medical Services;
  • Candela Laser Corporation: Launched his career in the industry with the company; managed programs for gastrointestinal/urology and dermatology. Also involved with grant proposal writing.

Dr. Kaul holds an MD in anesthesiology and an MPH in epidemiology/biostatistics from the Harvard School of Public Health.

Asiatic Clinical Research is a full-service contract research organization with a focus on Phase II - IV trials. The company undertakes clinical trials for drugs, biologics and medical devices. It has an in-house team providing turnkey services to conduct clinical trials. Headquartered in Bangalore, India, Asiatic also has additional offices and strategic partners who are located in Alpharetta, GA; Orem, UT; Marbella, Spain; and Bad Nauheim, Germany.



CONTACT:

Asiatic Clinical Research
Mithra Bindhu, Executive Director
678-805-4440, ext.102
[email protected]l.com
or
Leavitt Communications
Neal Leavitt
760-639-2900
[email protected]

KEYWORDS:   United States  North America  Georgia

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Medical Devices  Pharmaceutical  Research  Other Science  Science

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.